.
The ANswer within the microEnvironment: Malignant pleural mesothelioma resistance to Old and New drugs (ANEMONE)
Project/agreement No.
ES RTD/2023/08
Project funding
210 000.00 EUR
Project manager
Project realization
01.11.2022. - 31.10.2025.
Aim
The main goal of the research is to identify the principal factors that may influence the response of PM (Pleural Mesothelioma) patients to ICI (immune checkpoint inhibitors) treatment. Thus, the study has the following specific aims:
1) To obtain a precise characterisation of TME/TIM (Tumour microenvironment/ Tumour immune microenvironment) in clinical PM samples, using several morphological/ imaging tools (histology, immunostaining, radiomics, and MRI);
2) To evaluate the influence of genetic alteration and gene expression modulation on TME/TIM and ICI treatment response using tissue omics tools (genomics, transcriptomics and proteomics);
3) To identify the most discriminative features predictive of ICI treatment response by correlating pathological/ molecular finding with clinical/ radiological data, as well as by using in vito and in vivo models.
1) To obtain a precise characterisation of TME/TIM (Tumour microenvironment/ Tumour immune microenvironment) in clinical PM samples, using several morphological/ imaging tools (histology, immunostaining, radiomics, and MRI);
2) To evaluate the influence of genetic alteration and gene expression modulation on TME/TIM and ICI treatment response using tissue omics tools (genomics, transcriptomics and proteomics);
3) To identify the most discriminative features predictive of ICI treatment response by correlating pathological/ molecular finding with clinical/ radiological data, as well as by using in vito and in vivo models.
Description
Project coordinator: University of Padua (Italy)
Project partners: Rīga Stardiņš University (Latvia), Medical University of Graz (Austria), University of Coimbra (Portugal), Pisa University Hospital (Italy)
